Preferred Label : Lomitapide Mesylate;

NCIt synonyms : N-(2,2,2-Trifluoroethyl)-9-(4-(4-(((4'-(Trifluoromethyl)Biphenyl-2-yl)Carbonyl)Amino)Piperidin-1-yl)Butyl)-9H-Fluorene-9-Carboxamide Methanesulfonate; 9H-Fluorene-9-Carboxamide, N-(2,2,2-Trifluoroethyl)-9-(4-(4-(((4'-(Trifluoromethyl)(1,1'-Biphenyl)-2-yl)Carbonyl)Amino)-1-Piperidinyl)Butyl)-, Methanesulfonate; Lomitapide Mesilate;

NCIt definition : A methanesulfonic acid form of lomitapide, a small molecule inhibitor of microsomal triglyceride transfer protein.;

UNII : X4S83CP54E;

InChIKey : QKVKOFVWUHNEBX-UHFFFAOYSA-N;

CAS number : 202914-84-9;

Molecule name : AEGR-733; AEGR-733 Mesylate; BMS-201038-04; BMS-201038;

Chemical formula : C39H37F6N3O2.CH4O3S;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3505740/fr/lojuxta-lomitapide-hypercholesterolemie-familiale-homozygote
2024
false
false
false
France
Lomitapide Mesylate
Homozygous Familial Hypercholesterolemia
child
adolescent
evaluation of the transparency committee
lomitapide
Lomitapide Mesylate
mesylates

---
Summary Basis of Decision (SBD) for Juxtapid
Lomitapide mesylate, 5 mg, 10 mg and 20 mg, capsule, oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00224
2014
false
Canada
French
English
lomitapide
lomitapide
lomitapide
administration, oral
drug approval
canada
Familial hypercholesterolemia - homozygous (disorder)
hyperlipoproteinemia type ii
BMS201038
BMS201038
adult
anticholesteremic agents
anticholesteremic agents
rare diseases
drug interactions
treatment outcome
clinical trials, phase iii as topic
Lomitapide Mesylate
microsomal triglyceride transfer protein
carrier proteins
benzimidazoles
benzimidazoles
drug information

---
http://www.has-sante.fr/portail/jcms/c_1719428/fr/lojuxta-lomitapide-hypocholesterolemiant
2014
false
false
false
France
French
lomitapide
lomitapide
lomitapide
Lomitapide Mesylate
administration, oral
anticholesteremic agents
anticholesteremic agents
Familial hypercholesterolemia - homozygous (disorder)
hyperlipoproteinemia type ii
treatment outcome
adult
drug therapy, combination
rare diseases
clinical trials, phase iii as topic
insurance, health, reimbursement
guidelines for drug use
evaluation of the transparency committee
BMS201038
BMS201038
benzimidazoles
benzimidazoles

---
Nous contacter.
09/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.